RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
November 15 2020 - 7:30AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced that the Company plans to
present initial data from its Phase 1/2 clinical trial of FLX475 in
patients with multiple cancer indications in a premarket press
release and webcast on Monday, November 16, 2020.
RAPT will host a conference call accompanied by a slide
presentation at 8:30 a.m. ET on Monday, November 16th. The live
webcast and audio archive of the presentation may be accessed on
the RAPT Therapeutics website
at https://investors.rapt.com/events-and-presentations. The
call can be accessed by dialing (833) 672-0665 (domestic) or (929)
517-0344 (international) and refer to conference ID 6772479. The
webcast will be available for replay for two weeks. Please connect
to the website 10 minutes prior to the presentation to ensure
adequate time for any software downloads that may be necessary to
listen to the webcast.
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets, including hematopoietic progenitor kinase 1 (HPK1) and
general control nonderepressible 2 (GCN2), that are in the
discovery stage of development.
RAPT Media Contact:Angela
Bittingmedia@rapt.com(925) 202-6211
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024